Register for an account

X

Enter your name and email address below.

Your email address is used to log in and will not be shared or sold. Read our privacy policy.

X

Website access code

Enter your access code into the form field below.

If you are a Zinio, Nook, Kindle, Apple, or Google Play subscriber, you can enter your website access code to gain subscriber access. Your website access code is located in the upper right corner of the Table of Contents page of your digital edition.

Health

New Drug Could Boost Diabetics' Insulin Levels Naturally

D-briefBy Carl EngelkingMay 21, 2014 9:35 PM

Newsletter

Sign up for our email newsletter for the latest science news

shutterstock_144659519.jpg

Type 2 diabetes, the most common kind, results from too little insulin in the bloodstream, leading to high blood sugar levels and a host of other health problems. The disease is growing in prevalence and is intensive to manage---many diabetics do daily insulin injections and blood sugar testing---with fatal consequences if it's left out of control. Now scientists have opened the doorway to a new approach to diabetes treatment---rather than boosting insulin supply, instead slowing its disappearance---with the discovery of a molecule that inhibits insulin's degradation. The discovery could bring new therapeutic treatments for diabetics.

Controlling Sugars

In the recent study scientists focused on the behavior of insulin-degrading enzyme (IDE), which, as its name implies, breaks down insulin. Because in type 2 diabetes insulin levels are too low, blocking IDE has been a therapeutic approach of interest in treating the disease. Researchers sifted through more than 13,000 potential candidate molecules to find one, called 6bK, that bound to mouse IDE in a test tube. They then put 6bK to the test in live mice, some obese and some lean. The mice were given injections of the enzyme inhibitor and then an oral dose of glucose, simulating the sugar spike experienced after eating a meal. The mice treated with 6bK showed increased insulin levels and improved glucose clearance, both of which are problems for diabetics. The findings were published today in Nature

.

Future Treatments

The findings, researchers say, firmly establish IDE as a target of exploration among diabetes therapies. Researchers speculate that pre-meal medications that block IDE, rather than chronic treatments, could be developed based on the evidence presented in their study. With a target firmly planted on the infamous enzyme, future studies can take aim at finding new ways to help more than 10 percent of the U.S. population living with diabetes.

Photo credit: bikeriderlondon/Shutterstock

    2 Free Articles Left

    Want it all? Get unlimited access when you subscribe.

    Subscribe

    Already a subscriber? Register or Log In

    Want unlimited access?

    Subscribe today and save 70%

    Subscribe

    Already a subscriber? Register or Log In